- Home
- GRF vs LTRN Comparison
GRF vs LTRN Comparison
Compare GRF & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- LTRN
- Stock Information
- Founded
- GRF 1989
- LTRN 2013
- Country
- GRF United States
- LTRN United States
- Employees
- GRF N/A
- LTRN N/A
- Industry
- GRF Finance/Investors Services
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- GRF Finance
- LTRN Health Care
- Exchange
- GRF Nasdaq
- LTRN Nasdaq
- Market Cap
- GRF 42.6M
- LTRN 49.9M
- IPO Year
- GRF N/A
- LTRN 2020
- Fundamental
- Price
- GRF $10.81
- LTRN $3.26
- Analyst Decision
- GRF
- LTRN Strong Buy
- Analyst Count
- GRF 0
- LTRN 1
- Target Price
- GRF N/A
- LTRN $25.00
- AVG Volume (30 Days)
- GRF 3.0K
- LTRN 102.6K
- Earning Date
- GRF 01-01-0001
- LTRN 11-12-2025
- Dividend Yield
- GRF 3.70%
- LTRN N/A
- EPS Growth
- GRF N/A
- LTRN N/A
- EPS
- GRF 1.16
- LTRN N/A
- Revenue
- GRF N/A
- LTRN N/A
- Revenue This Year
- GRF N/A
- LTRN N/A
- Revenue Next Year
- GRF N/A
- LTRN N/A
- P/E Ratio
- GRF $8.15
- LTRN N/A
- Revenue Growth
- GRF N/A
- LTRN N/A
- 52 Week Low
- GRF $7.93
- LTRN $2.55
- 52 Week High
- GRF $10.19
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- GRF 49.06
- LTRN 31.85
- Support Level
- GRF $10.61
- LTRN $3.42
- Resistance Level
- GRF $10.90
- LTRN $3.55
- Average True Range (ATR)
- GRF 0.16
- LTRN 0.25
- MACD
- GRF -0.00
- LTRN -0.03
- Stochastic Oscillator
- GRF 57.98
- LTRN 21.50
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.